从循证医学角度谈吗替麦考酚酯抗风湿作用的定位

吗替麦考酚酯(MMF)作为免疫抑制剂,近十余年来逐渐被用于治疗风湿免疫疾病,尤其是治疗狼疮肾炎(LN).从近年的国际红斑狼疮学术会议、美国风湿病学会(ACR)年会、欧洲风湿病学会联合会(EULAR)年会、亚太区风湿病学会联合会(APLAR)年会等的交流中,以及在一些迁移到美国、加拿大、欧洲等国继续治疗的LN患者中,均可得知世界各国的风湿科和肾科医生,均普遍在运用MMF治疗红斑狼疮.     

第二届国际防痨和肺部疾病联合会亚太区学术大暨2009年中国防痨协会学术会议在北京成功举行

“第二届国际防痨和肺部疾病联合会亚太区学术大会”于2009年9月9日至12日在北京举行。会议的主题为“耐药结核病的预防和控制”。国际防痨和肺部疾病联合会执行主任Dr.Nils E.Billo、秘书长Dr.Camilo Roa Jr,国际防痨和肺部疾病联合会亚太区主席Mr.Yeop Jr、秘书长Mr.Sahul Hamid,世界卫生组织西太区顾问Dr.Pieter Van Maaren等负责人,来自亚洲、太平洋地区37个国家和地区以及中国结核病领域的著名专家、学者、各地代表共1 260人参加了会议。     

对ASMBS现任主席Raul Rosenthal教授的专访

<正>访谈时间:2015年4月10日访谈地点:国际减重与代谢外科联盟亚太区大会(韩国首尔)访谈方式:当面采访采访者(Y):杨景哥采访者简介:外科博士,暨南大学附属第一医院普通外科、肥胖与代谢病外科,哈佛大学医学院访问学者,中华肥胖与代谢病电子杂志编辑部主任。被采访者(R):Raul Rosenthal,M.D,被采访者简介:ASMBS现任主席,美国胃肠道与内镜外科医生学院(SAGES)全球倡议委员会主席,国际肥胖     

第一届亚太区结核病和肺部疾病会议简报

国际防痨和肺部疾病联盟(IUATLD)第一届亚太区结核病和肺部疾病会议于2007年8月1—5日在马来西亚首都吉隆坡举行,IUATLD总部、WHO西太区总部的专家和来自亚洲、太平洋地区的1 200多名专家学者参加了此次会议。中国防痨协会理事长端木宏谨教授、副秘书长王甦民教授代表中国防痨协会参加了此次会议,中国CDC及天津、上海、内蒙古、广西等省市自治区的20名专家学者也参加了此次会议。会议内容包括了结核病和其他呼吸系统疾病的研讨。在结核病领域中工作的专家学者从结核病的预防控制、基础研究、临床检验新技术、耐药结核病特别是耐多药结核病的治疗等各个方面交流了近年来的经验和研究进展,WHO和IUATLD的专家也介绍了结核病控制的目标及工作设想。在会议的最后由大会科学委员会主席报告了本次会议的产出:加强结核病的基础研究和预防控制工作,重视对耐药结核病特别是耐多药结核病的发现、治疗和管理;重视对HIV/艾滋病合并结核病的研究和治疗;重视移民/流动人口结核病的控制。在会议的闭幕式上播放了介绍中国结核病控制和古都北京的短片,受到与会专家学者的热烈欢迎。本次会议主席宣布,经国际防痨和肺部疾病联盟(IUATLD)亚太区执委会讨论一...     

荔枝核颗粒治疗慢性乙型肝炎的疗效观察

目的:观察荔枝核颗粒治疗慢性乙型肝炎的临床疗效.方法:对照组46例采用一般护肝治疗,治疗组48例在一般护肝治疗用药基础上加用荔枝核颗粒治疗,治疗时间两组均为6个月,通过肝功能指标及肝纤维化指标评价疗效.结果:治疗组及对照组患者肝功能指标及肝纤维化指标均有改善,但在部分指标上,治疗组优于对照组.结论:荔枝核颗粒对慢性乙型肝炎有较好的治疗作用.     

茯白方对肝炎肝硬化患者胆碱脂酶活力的影响

目的:探讨茯白方对肝炎肝硬化患者血清胆碱脂酶活力的影响.方法:将69例肝炎肝硬化患者随机分为治疗1组22例,治疗2组23例与对照组24例.对照组患者采用基础治疗,治疗1组患者在基础治疗上加服茯白方,12周为1个疗程;治疗2组患者在基础治疗上也加服茯白方,24周为1个疗程.观察治疗12周、24周时3组患者血清胆碱脂酶(ChE)变化情况.结果:治疗1组、治疗2组患者在改善症状、提高血清胆碱脂酶(ChE)方面,明显优于对照组.结论:茯白方能提高肝炎肝硬化患者血清胆碱脂酶(ChE)活力,且中远期效果更为显著、持久.     

第13届世界艾滋病大会掠影

1 殷副部长在艾滋病大会期间与美国NIAID所长Tony Fanci博士等NIH官员讨论中美两国艾滋病防治领域的合作.2 卫生部殷大奎副部长、陈贤义副司长、国合司高细水副司长、国合司郭继东先生、卫生部艾滋病预防与控制中心邵一鸣教授及默克公司亚太区市场总监Chris Tan、默克公司副总裁GuyMcDonald合影.     

经肝动脉自体骨髓干细胞移植联合奥曲肽治疗肝硬化顽固性腹水14例

目的:研究经肝动脉自体骨髓干细胞移植联合奥曲肽治疗肝硬化顽固性腹水的临床疗效.方法:33例肝硬化顽固性腹水患者被随机分为两组,治疗组(14例)在常规治疗药物治疗上行经肝动脉自体骨髓干细胞移植后,再加用奥曲肽,对照组(19例)在常规治疗药物治疗上加奥曲肽.观察患者治疗后的腹围、食欲、尿量、双下肢浮肿、腹水消退情况及血清A...     

352例食管疾病的内镜治疗

食管静脉曲张破裂出血、食管狭窄以及贲门失弛缓症等均为临床上的常见的食管疾病.1983年以来作者对这些疾病进行了内镜下硬化治疗及扩张治疗.1 食管静脉曲张出血:共治疗了283例,将资料完整的231例报告如下:     

内镜黏膜下剥离术对治疗早期胃食管癌的进展

胃癌一直是亚太区第2大致死癌病,而食管鳞状细胞癌也常发生在亚洲癌症高发带,包括东土耳其、伊拉克、伊朗、中国及日本等。晚期胃癌5年存活率仅20％～40％,食管鳞状细胞癌5年存活率更只有10％～20％。因为这些癌症发现时一般都在中晚期。Everett等曾报道世界上早期胃癌的5年存活率可高达90％以上。本文将回顾内镜对早期胃食管癌诊断的发展,以及黏膜切除术（EMR）和黏膜下剥离术（ESD）对早期胃食管癌的治疗效果。     

Autoimmune hepatitis caused by acute hepatitis due to hepatitis A virus

We describe the case of a 27-year-old man who presented acute hepatitis due to hepatitis A virus infection. Over the following weeks he consistently presented elevated transaminase levels and jaundice. Antinuclear and anti-smooth muscle antibodies, hypergammaglobulinemia and periportal necrosis were detected in the liver biopsy. The patient was diagnosed with autoimmune hepatitis and responded well to treatment with immunosuppressive drugs. This case, as well as other published reports, suggest that in certain individuals, acute hepatitis A may be the decisive factor leading to autoimmune hepatitis.     

Economics of chronic hepatitis B and hepatitis C

Although not all patients develop progressive liver disease, chronic hepatitis B and chronic hepatitis C infections cause substantial morbidity and mortality worldwide. To address this need, many new antiviral treatments have become available over the past 10 years. While safety, efficacy, and therapeutic indications have been well established for these agents, the economics of antiviral treatment have become increasingly a focus of discussion for physicians, policymakers, and health payers. In this paper, we will elucidate some economic principles using examples from the treatment of hepatitis B and C. In particular, we will examine the considerations in estimating drug costs, methods for performing economic analyses and lastly summarize published cost-effectiveness analyses for antiviral treatments of chronic hepatitis B and chronic hepatitis C. This review should help clinicians understand economic issues regarding new drugs and answer questions about whether the clinical benefit provided by a medication justifies its expense.     

Autoimmune hepatitis versus viral hepatitis C

Abstract: Numerous viruses are capable of inducing the syndrome of chronic hepatitis. Among them are the hepatitis B, C and D viruses. Out of the most common agents of chronic hepatitis, the hepatitis C virus has been found to be strikingly associated with autoimmune diseases and serological markers of autoimmunity. Conversely, the syndrome of genuine autoimmune hepatitis lacks evidence of previous or ongoing virus infection and is diagnosed by additionally excluding metabolic, toxic, and genetic causes of chronic hepatitis, and by the response to immunosuppressive treatment. This review article summarizes the current knowledge of hepatotropic virus-induced autoimmunity. It focuses on the present molecular and immunological definitions, the clinical and molecular distinction between autoimmune hepatitis and chronic viral hepatitis and the implications for the safe and efficacious therapy of these disease entities.     

Isoniazid-rifampin-induced hepatitis in hepatitis B carriers

From January 1984-December 1987, 1783 patients received combination therapy of isoniazid, rifampin, and ethambutol for the control of tuberculosis. Forty-two developed symptomatic hepatitis during the period of treatment. Fifteen were hepatitis B virus carriers, and the remaining 27 were noncarriers. The peak serum transaminase and bilirubin levels were higher in carriers. Seven carriers died of fulminant or subacute hepatic failure, and only 1 noncarrier died. Eleven carriers had detectable serum hepatitis B virus deoxyribonucleic acid during the acute stage of hepatitis. The roles of isoniazid-rifampin combination therapy and hepatitis B virus in the adverse outcomes of carriers were discussed.